QRxPharma Pty Ltd.
This article was originally published in Start Up
Executive Summary
QRx's lead (Phase II) candidate is a morphine/oxycodone combination that takes advantage of the synergistic effect of those two opioids when combined to produce a more potent painkiller, with fewer side effects, than morphine administered alone. The company is also developing an extended-release version of the drug and has a platform for discovering venom-based therapeutics.